

# Yasuko Mori

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5552114/publications.pdf>

Version: 2024-02-01

114  
papers

3,740  
citations

182225

30  
h-index

169272

56  
g-index

123  
all docs

123  
docs citations

123  
times ranked

3349  
citing authors

#	ARTICLE	IF	CITATIONS
1	Serum Soluble OX40 as a Diagnostic and Prognostic Biomarker for Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 558-565.e4.	2.0	10
2	Role of the Arginine Cluster in the Disordered Domain of Herpes Simplex Virus 1 UL34 for the Recruitment of ESCRT-III for Viral Primary Envelopment. <i>Journal of Virology</i> , 2022, 96, JVI0170421.	1.5	15
3	Viral shedding and the durability of IgG antibodies to SARS-CoV-2. <i>Microbiology and Immunology</i> , 2022, , .	0.7	1
4	Cross-Neutralizing Breadth and Longevity Against SARS-CoV-2 Variants After Infections. <i>Frontiers in Immunology</i> , 2022, 13, 773652.	2.2	9
5	Large-scale serosurveillance of COVID-19 in Japan: Acquisition of neutralizing antibodies for Delta but not for Omicron and requirement of booster vaccination to overcome the Omicron's outbreak. <i>PLoS ONE</i> , 2022, 17, e0266270.	1.1	11
6	Siglec-7 mediates varicella-zoster virus infection by associating with glycoprotein B. <i>Biochemical and Biophysical Research Communications</i> , 2022, 607, 67-72.	1.0	4
7	Induction of High Neutralizing Activity Against Both Omicron BA.2 and Omicron BA.1 by Coronavirus Disease 2019 Messenger RNA Booster Vaccination. <i>Journal of Infectious Diseases</i> , 2022, 226, 1481-1483.	1.9	5
8	Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine. <i>JAMA Network Open</i> , 2022, 5, e2210780.	2.8	27
9	Regulation of Siglec-7-mediated varicella-zoster virus infection of primary monocytes by cis-ligands. <i>Biochemical and Biophysical Research Communications</i> , 2022, 613, 41-46.	1.0	1
10	Diligent Medical Activities of a Publicly Designated Medical Institution for Infectious Diseases Pave the Way for Overcoming COVID-19: A Positive Message to People Working at the Cutting Edge. <i>Clinical Infectious Diseases</i> , 2021, 72, 723-724.	2.9	12
11	Seroepidemiological Survey of the Antibody for Severe Acute Respiratory Syndrome Coronavirus 2 with Neutralizing Activity at Hospitals: A Cross-sectional Study in Hyogo Prefecture, Japan. <i>JMA Journal</i> , 2021, 4, 41-49.	0.6	10
12	The Combination of gQ1 and gQ2 in Human Herpesvirus 6A and 6B Regulates the Viral Tetramer Function for Their Receptor Recognition. <i>Journal of Virology</i> , 2021, 95, .	1.5	3
13	Seroepidemiological study of SARS-CoV-2 infection in East Java, Indonesia. <i>PLoS ONE</i> , 2021, 16, e0251234.	1.1	21
14	The Roseoloviruses Downregulate the Protein Tyrosine Phosphatase PTPRC (CD45). <i>Journal of Virology</i> , 2021, 95, e0162820.	1.5	7
15	Massive surge of mRNA expression of clonal B-cell receptor in patients with COVID-19. <i>Heliyon</i> , 2021, 7, e07748.	1.4	4
16	Development of combination adjuvant for efficient T cell and antibody response induction against protein antigen. <i>PLoS ONE</i> , 2021, 16, e0254628.	1.1	4
17	Cross-Neutralizing Activity Against SARS-CoV-2 Variants in COVID-19 Patients: Comparison of 4 Waves of the Pandemic in Japan. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab430.	0.4	18
18	Human Herpesvirus 6A Tegument Protein U14 Induces NF- $\kappa$ B Signaling by Interacting with p65. <i>Journal of Virology</i> , 2021, 95, e0126921.	1.5	6

#	ARTICLE	IF	CITATIONS
19	The Neutralizing Antibody Response against Severe Acute Respiratory Syndrome Coronavirus 2 and the Cytokine/Chemokine Release in Patients with Different Levels of Coronavirus Diseases 2019 Severity: Cytokine Storm Still Persists Despite Viral Disappearance in Critical Patients. <i>JMA Journal</i> , 2021, 4, 1-7.	0.6	5
20	Early Differences in Cytokine Production by Severity of Coronavirus Disease 2019. <i>Journal of Infectious Diseases</i> , 2021, 223, 1145-1149.	1.9	80
21	Structural basis for the interaction of human herpesvirus 6B tetrameric glycoprotein complex with the cellular receptor, human CD134. <i>PLoS Pathogens</i> , 2020, 16, e1008648.	2.1	3
22	Role of Phosphatidylethanolamine Biosynthesis in Herpes Simplex Virus 1-Infected Cells in Progeny Virus Morphogenesis in the Cytoplasm and in Viral Pathogenicity <i>In Vivo</i> . <i>Journal of Virology</i> , 2020, 94, .	1.5	13
23	Tetrameric glycoprotein complex gH/gL/gQ1/gQ2 is a promising vaccine candidate for human herpesvirus 6B. <i>PLoS Pathogens</i> , 2020, 16, e1008609.	2.1	10
24	Comprehensive Screening of Mouse T-Cell Epitopes in Human Herpesvirus 6B Glycoprotein H/L/Q1/Q2 Tetramer Complex. <i>Journal of Immunology Research</i> , 2020, 2020, 1-13.	0.9	1
25	Human herpesvirus 6A U27 plays an essential role for the virus propagation. <i>Microbiology and Immunology</i> , 2020, 64, 703-711.	0.7	1
26	ESCRT-III controls nuclear envelope deformation induced by progerin. <i>Scientific Reports</i> , 2020, 10, 18877.	1.6	12
27	An Animal Model That Mimics Human Herpesvirus 6B Pathogenesis. <i>Journal of Virology</i> , 2020, 94, .	1.5	7
28	Title is missing!. , 2020, 16, e1008648.		0
29	Title is missing!. , 2020, 16, e1008648.		0
30	Title is missing!. , 2020, 16, e1008648.		0
31	Title is missing!. , 2020, 16, e1008648.		0
32	Entry of betaherpesviruses. <i>Advances in Virus Research</i> , 2019, 104, 283-312.	0.9	16
33	Sleep Shortage Is Associated With Postherpetic Neuralgia Development Through Hyperesthesia and Acute Pain Intensity: A Community-Based Prospective Cohort Study. <i>Pain Practice</i> , 2019, 19, 476-483.	0.9	13
34	Identification of CD4 and H-2Kd-restricted cytotoxic T lymphocyte epitopes on the human herpesvirus 6B glycoprotein Q1 protein. <i>Scientific Reports</i> , 2019, 9, 3911.	1.6	4
35	Humanization of Murine Neutralizing Antibodies against Human Herpesvirus 6B. <i>Journal of Virology</i> , 2019, 93, .	1.5	6
36	Direct RNA sequencing on nanopore arrays redefines the transcriptional complexity of a viral pathogen. <i>Nature Communications</i> , 2019, 10, 754.	5.8	200

#	ARTICLE	IF	CITATIONS
37	Human CD134 (OX40) expressed on T cells plays a key role for human herpesvirus 6B replication after allogeneic hematopoietic stem cell transplantation. <i>Journal of Clinical Virology</i> , 2018, 102, 50-55.	1.6	16
38	The Neutralizing Linear Epitope of Human Herpesvirus 6A Glycoprotein B Does Not Affect Virus Infectivity. <i>Journal of Virology</i> , 2018, 92, .	1.5	3
39	The human vascular endothelial cell line HUV-EC-C harbors the integrated HHV-6B genome which remains stable in long term culture. <i>Cytotechnology</i> , 2018, 70, 141-152.	0.7	6
40	Glycoproteins of HHV-6A and HHV-6B. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1045, 145-165.	0.8	5
41	Structural Aspects of Betaherpesvirus-Encoded Proteins. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1045, 227-249.	0.8	1
42	Cell Culture Systems To Study Human Herpesvirus 6A/B Chromosomal Integration. <i>Journal of Virology</i> , 2017, 91, .	1.5	30
43	Crystal Structure of the DNA-Binding Domain of Human Herpesvirus 6A Immediate Early Protein 2. <i>Journal of Virology</i> , 2017, 91, .	1.5	10
44	Relationship between cell-mediated immunity to Varicella-Zoster virus and aging in subjects from the community-based Shozu Herpes Zoster study. <i>Journal of Medical Virology</i> , 2017, 89, 313-317.	2.5	10
45	Purification, Crystallization and X-ray Diffraction Study of the C-terminal Domain of Human Herpesvirus 6A Immediate Early Protein 2. <i>Kobe Journal of Medical Sciences</i> , 2017, 62, E142-E149.	0.2	1
46	Crystal Structure of Human Herpesvirus 6B Tegument Protein U14. <i>PLoS Pathogens</i> , 2016, 12, e1005594.	2.1	12
47	Preferential expression of CD134, an HHV-6 cellular receptor, on CD4T cells in drug-induced hypersensitivity syndrome (DIHS)/drug reaction with eosinophilia and systemic symptoms (DRESS). <i>Journal of Dermatological Science</i> , 2016, 83, 151-154.	1.0	29
48	Human Herpesvirus 6A U14 Is Important for Virus Maturation. <i>Journal of Virology</i> , 2016, 90, 1677-1681.	1.5	7
49	Clinical and immunologic features of recurrent herpes zoster (HZ). <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 950-956.e1.	0.6	19
50	Comprehensive analysis of serum cytokines/chemokines in febrile children with primary human herpes virus-6B infection. <i>Journal of Infection and Chemotherapy</i> , 2016, 22, 593-598.	0.8	9
51	Human herpesvirus 6 U11 protein is critical for virus infection. <i>Virology</i> , 2016, 489, 151-157.	1.1	13
52	Cytoplasmic tail domain of glycoprotein B is essential for HHV-6 infection. <i>Virology</i> , 2016, 490, 1-5.	1.1	4
53	Use of a current varicella vaccine as a live polyvalent vaccine vector. <i>Vaccine</i> , 2016, 34, 296-298.	1.7	3
54	The Telomeric Repeats of Human Herpesvirus 6A (HHV-6A) Are Required for Efficient Virus Integration. <i>PLoS Pathogens</i> , 2016, 12, e1005666.	2.1	58

#	ARTICLE	IF	CITATIONS
55	Incidences of Herpes Zoster and Postherpetic Neuralgia in Japanese Adults Aged 50 Years and Older From a Community-based Prospective Cohort Study: The SHEZ Study. <i>Journal of Epidemiology</i> , 2015, 25, 617-625.	1.1	51
56	The human herpesvirus 6 U21â€“U24 gene cluster is dispensable for virus growth. <i>Microbiology and Immunology</i> , 2015, 59, 48-53.	0.7	7
57	Human Herpesvirus-6 U14 Induces Cell-Cycle Arrest in G2/M Phase by Associating with a Cellular Protein, EDD. <i>PLoS ONE</i> , 2015, 10, e0137420.	1.1	16
58	Determinants of Human CD134 Essential for Entry of Human Herpesvirus 6B. <i>Journal of Virology</i> , 2015, 89, 10125-10129.	1.5	15
59	A Human Herpesvirus 6A-Encoded MicroRNA: Role in Viral Lytic Replication. <i>Journal of Virology</i> , 2015, 89, 2615-2627.	1.5	45
60	Maturation of Human Herpesvirus 6A Glycoprotein O Requires Coexpression of Glycoprotein H and Glycoprotein L. <i>Journal of Virology</i> , 2015, 89, 5159-5163.	1.5	9
61	A recombinant varicella vaccine harboring a respiratory syncytial virus gene induces humoral immunity. <i>Vaccine</i> , 2015, 33, 6085-6092.	1.7	1
62	Sialic Acids on Varicella-Zoster Virus Glycoprotein B Are Required for Cell-Cell Fusion. <i>Journal of Biological Chemistry</i> , 2015, 290, 19833-19843.	1.6	29
63	VZV skin-test reaction, but not antibody, is an important predictive factor for postherpetic neuralgia. <i>Journal of Dermatological Science</i> , 2015, 79, 235-240.	1.0	22
64	Detailed Study of the Interaction between Human Herpesvirus 6B Glycoprotein Complex and Its Cellular Receptor, Human CD134. <i>Journal of Virology</i> , 2014, 88, 10875-10882.	1.5	23
65	MHC class I molecules are incorporated into human herpesvirusâ€™6 viral particles and released into the extracellular environment. <i>Microbiology and Immunology</i> , 2014, 58, 119-125.	0.7	22
66	Human herpesvirusâ€™6<sc>A</sc> g<sc>Q</sc>1 and g<sc>Q</sc>2 are critical for human<sc>CD</sc>46 usage. <i>Microbiology and Immunology</i> , 2014, 58, 22-30.	0.7	23
67	Varicella-Zoster Virus ORF49 Functions in the Efficient Production of Progeny Virus through Its Interaction with Essential Tegument Protein ORF44. <i>Journal of Virology</i> , 2014, 88, 188-201.	1.5	22
68	Characterization of the human herpesvirus 6A U23 gene. <i>Virology</i> , 2014, 450-451, 98-105.	1.1	8
69	Classification of HHV-6A and HHV-6B as distinct viruses. <i>Archives of Virology</i> , 2014, 159, 863-870.	0.9	292
70	Human herpesvirus 6 gM/gN complex interacts with v-SNARE in infected cells. <i>Journal of General Virology</i> , 2014, 95, 2769-2777.	1.3	6
71	An inverse correlation of VZV skin-test reaction, but not antibody, with severity of herpes zoster skin symptoms and zoster-associated pain. <i>Journal of Dermatological Science</i> , 2013, 69, 243-249.	1.0	38
72	Novel polyvalent live vaccine against varicellaâ€™zoster and mumps virus infections. <i>Microbiology and Immunology</i> , 2013, 57, 704-714.	0.7	8

#	ARTICLE	IF	CITATIONS
73	Identification of the Human Herpesvirus 6A gQ1 Domain Essential for Its Functional Conformation. <i>Journal of Virology</i> , 2013, 87, 7054-7063.	1.5	9
74	CD134 is a cellular receptor specific for human herpesvirus-6B entry. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 9096-9099.	3.3	140
75	The Shozu Herpes Zoster (SHEZ) Study: Rationale, Design, and Description of a Prospective Cohort Study. <i>Journal of Epidemiology</i> , 2012, 22, 167-174.	1.1	21
76	Complementation of the Function of Glycoprotein H of Human Herpesvirus 6 Variant A by Glycoprotein H of Variant B in the Virus Life Cycle. <i>Journal of Virology</i> , 2012, 86, 8492-8498.	1.5	26
77	A community-based survey of varicella-zoster virus-specific immune responses in the elderly. <i>Journal of Clinical Virology</i> , 2012, 55, 46-50.	1.6	33
78	Features of Human Herpesvirus-6A and -6B Entry. <i>Advances in Virology</i> , 2012, 2012, 1-6.	0.5	9
79	Multiple Reversions of an IL2RG Mutation Restore T cell Function in an X-linked Severe Combined Immunodeficiency Patient. <i>Journal of Clinical Immunology</i> , 2012, 32, 690-697.	2.0	24
80	Human herpesvirus 6 glycoprotein M is essential for virus growth and requires glycoprotein N for its maturation. <i>Virology</i> , 2012, 429, 21-28.	1.1	15
81	Human herpesvirus 6 major immediate early promoter has strong activity in T cells and is useful for heterologous gene expression. <i>Virology Journal</i> , 2011, 8, 9.	1.4	8
82	Analysis of a Neutralizing Antibody for Human Herpesvirus 6B Reveals a Role for Glycoprotein Q1 in Viral Entry. <i>Journal of Virology</i> , 2011, 85, 12962-12971.	1.5	28
83	Human Herpesvirus 6 Glycoprotein Complex Formation Is Required for Folding and Trafficking of the gH/gL/gQ1/gQ2 Complex and Its Cellular Receptor Binding. <i>Journal of Virology</i> , 2011, 85, 11121-11130.	1.5	34
84	Varicella-Zoster Virus Glycoprotein M. <i>Current Topics in Microbiology and Immunology</i> , 2010, 342, 147-154.	0.7	1
85	Rapid and efficient introduction of a foreign gene into bacterial artificial chromosome-cloned varicella vaccine by Tn7-mediated site-specific transposition. <i>Virology</i> , 2010, 402, 215-221.	1.1	8
86	Characterization of varicella-zoster virus-encoded ORF0 gene—Comparison of parental and vaccine strains. <i>Virology</i> , 2010, 405, 280-288.	1.1	31
87	Human herpesvirus 6 encoded glycoprotein Q1 gene is essential for virus growth. <i>Virology</i> , 2010, 407, 360-367.	1.1	47
88	Characterization of the Varicella-Zoster Virus ORF50 Gene, Which Encodes Glycoprotein M. <i>Journal of Virology</i> , 2010, 84, 3488-3502.	1.5	19
89	Myelin-associated glycoprotein mediates membrane fusion and entry of neurotropic herpesviruses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 866-871.	3.3	140
90	Human herpesvirus-6 entry into host cells. <i>Future Microbiology</i> , 2010, 5, 1015-1023.	1.0	16

#	ARTICLE	IF	CITATIONS
91	Comparison of Varicella-Zoster Virus-Specific Immunity of Patients with Diabetes Mellitus and Healthy Individuals. <i>Journal of Infectious Diseases</i> , 2009, 200, 1606-1610.	1.9	70
92	Recent topics related to human herpesvirus 6 cell tropism. <i>Cellular Microbiology</i> , 2009, 11, 1001-1006.	1.1	69
93	Human herpesvirus 6 envelope components enriched in lipid rafts: evidence for virion-associated lipid rafts. <i>Virology Journal</i> , 2009, 6, 127.	1.4	17
94	Human Herpesvirus-6 Induces MVB Formation, and Virus Egress Occurs by an Exosomal Release Pathway. <i>Traffic</i> , 2008, 9, 1728-1742.	1.3	160
95	Varicella-zoster virus ORF1 gene product is a tail-anchored membrane protein localized to plasma membrane and trans-Golgi network in infected cells. <i>Virology</i> , 2008, 377, 289-295.	1.1	9
96	Human herpesvirus-6 infection induces the reorganization of membrane microdomains in target cells, which are required for virus entry. <i>Virology</i> , 2008, 378, 265-271.	1.1	41
97	Measurement of Varicella-Zoster Virus (VZV)-Specific Cell-Mediated Immunity: Comparison between VZV Skin Test and Interferon- $\gamma$ Enzyme-Linked Immunospot Assay. <i>Journal of Infectious Diseases</i> , 2008, 198, 1327-1333.	1.9	59
98	Varicella-Zoster Virus Glycoprotein M Homolog Is Glycosylated, Is Expressed on the Viral Envelope, and Functions in Virus Cell-to-Cell Spread. <i>Journal of Virology</i> , 2008, 82, 795-804.	1.5	31
99	Deletion in Open Reading Frame 49 of Varicella-Zoster Virus Reduces Virus Growth in Human Malignant Melanoma Cells but Not in Human Embryonic Fibroblasts. <i>Journal of Virology</i> , 2007, 81, 12654-12665.	1.5	31
100	Cloning of full length genome of varicella-zoster virus vaccine strain into a bacterial artificial chromosome and reconstitution of infectious virus. <i>Vaccine</i> , 2007, 25, 5006-5012.	1.7	29
101	Generation of a recombinant Oka varicella vaccine expressing mumps virus hemagglutinin-neuraminidase protein as a polyvalent live vaccine. <i>Vaccine</i> , 2007, 25, 8741-8755.	1.7	28
102	Human herpesvirus 6 envelope cholesterol is required for virus entry. <i>Journal of General Virology</i> , 2006, 87, 277-285.	1.3	59
103	Human Herpesvirus 6 Open Reading Frame U14 Protein and Cellular p53 Interact with Each Other and Are Contained in the Virion. <i>Journal of Virology</i> , 2005, 79, 13037-13046.	1.5	43
104	Intracellular Processing of Human Herpesvirus 6 Glycoproteins Q1 and Q2 into Tetrameric Complexes Expressed on the Viral Envelope. <i>Journal of Virology</i> , 2004, 78, 7969-7983.	1.5	78
105	Discovery of a Second Form of Tripartite Complex Containing gH-gL of Human Herpesvirus 6 and Observations on CD46. <i>Journal of Virology</i> , 2004, 78, 4609-4616.	1.5	78
106	Cloning of the varicella-zoster virus genome as an infectious bacterial artificial chromosome in <i>Escherichia coli</i> . <i>Vaccine</i> , 2004, 22, 4069-4074.	1.7	70
107	The Human Herpesvirus 6 U100 Gene Product Is the Third Component of the gH-gL Glycoprotein Complex on the Viral Envelope. <i>Journal of Virology</i> , 2003, 77, 2452-2458.	1.5	60
108	Human Herpesvirus 6 Variant A Glycoprotein H-Glycoprotein L-Glycoprotein Q Complex Associates with Human CD46. <i>Journal of Virology</i> , 2003, 77, 4992-4999.	1.5	98

#	ARTICLE	IF	CITATIONS
109	Comparison of the Complete DNA Sequences of the Oka Varicella Vaccine and Its Parental Virus. Journal of Virology, 2002, 76, 11447-11459.	1.5	174
110	Human Herpesvirus 6 Variant A but Not Variant B Induces Fusion from Without in a Variety of Human Cells through a Human Herpesvirus 6 Entry Receptor, CD46. Journal of Virology, 2002, 76, 6750-6761.	1.5	100
111	Human herpesvirus-6 rep/U94 gene product has single-stranded DNA-binding activity. Journal of General Virology, 2002, 83, 847-854.	1.3	68
112	Human herpesvirus 8-encoded interleukin-6 homologue (viral IL-6) induces endogenous human IL-6 secretion. Journal of Medical Virology, 2000, 61, 332-335.	2.5	69
113	Comparison of the Complete DNA Sequences of Human Herpesvirus 6 Variants A and B. Journal of Virology, 1999, 73, 8053-8063.	1.5	224
114	Analysis of Human Herpesvirus 6 U3 Gene, which Is a Positional Homolog of Human Cytomegalovirus UL 24 Gene. Virology, 1998, 249, 129-139.	1.1	27